2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Trilaciclib, Placebo, Topotecan - Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | G1 Therapeutics, Inc. | 123 | 2015-10-05 | 2025-09-25 |
| Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Carboplatin, Placebo, Trilaciclib - Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | G1 Therapeutics, Inc. | 122 | 2015-06-26 | 2020-08-21 |
United States (2) · Belgium (1) · Bosnia and Herzegovina (1) · Croatia (1) · France (1) · Georgia (1) · Hungary (1) · Moldova (1) · North Macedonia (1) · Poland (1) · Serbia (1) · Slovakia (1) · Slovenia (1) · Spain (1)
PMID 33595690, PMID 34405547, PMID 34408488, PMID 31504118, PMID 33004541, PMID 33123968, PMID 35842567, PMID 39113428
2016 (2)